<DOC>
	<DOCNO>NCT00005863</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Colony-stimulating factor filgrastim may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect chemotherapy . It yet know whether combination chemotherapy filgrastim and/or tretinoin effective combination chemotherapy alone acute myeloid leukemia . PURPOSE : This randomized phase III trial study combination chemotherapy filgrastim and/or tretinoin see well work compare combination chemotherapy alone treat patient acute myeloid leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Filgrastim and/or Tretinoin Treating Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Compare standard induction chemotherapy cytarabine , daunorubicin , etoposide vs fludarabine cytarabine term achievement remission , reason remission failure , duration remission , survival , toxicity , supportive care need patient high risk acute myeloid leukemia . - Determine use filgrastim ( G-CSF ) tretinoin administer follow chemotherapy improve outcome patient population . - Determine impact treatment regimens quality life patient . OUTLINE : This randomize , control , multicenter study . Patients stratify accord type disease ( resistant v refractory v relapse vs adverse cytogenetic ) , age ( 15 vs 15 29 , vs 30 49 vs 50-59 v 60-69 v 70 ) , performance status , de novo secondary leukemia . Patients relapse disease stratify accord duration first remission ( le 6 month vs 6 12 month vs 12 month ) , prior transplantation ( yes v ) . Patients randomize one two treatment arm induction chemotherapy . - Arm I : Patients receive induction chemotherapy consist cytarabine IV every 12 hour day 1-10 , daunorubicin IV day 1 , 3 , 5 etoposide IV 1 hour day 1-5 . Patients receive second course therapy cytarabine IV every 12 hour day 1-8 daunorubicin etoposide course 1 . - Arm II : Patients receive 2 course induction chemotherapy consist fludarabine IV 30 minute follow cytarabine IV 4 hour day 1-5 . Patients randomize one two treatment arm colony stimulate factor therapy . - Arm I : Patients receive filgrastim ( G-CSF ) subcutaneously IV daily begin day 1 course induction chemotherapy continue blood count recover , maximum 28 day . - Arm II : Patients receive G-CSF follow induction chemotherapy . Patients randomize one two treatment arm retinoid therapy . - Arm I : Patients receive oral tretinoin daily begin day 1 induction chemotherapy continue maximum 90 day . - Arm II : Patients receive retinoid therapy follow induction chemotherapy . Following completion induction chemotherapy , patient achieve complete remission blood count recovery may receive subsequent therapy consist consolidation chemotherapy and/or autologous allogeneic transplantation . Quality life assess 3 month . PROJECTED ACCRUAL : Approximately 800-1,000 patient accrue study within 4-5 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis acute myeloid leukemia ( AML ) include de novo secondary AML , preexist myelodysplastic syndrome Overt resistant disease 15 % bone marrow blast induction course Primary refractory disease Failure achieve first complete remission least 2 induction course Relapse first remission 5 % bone marrow blast Complete partial remission follow 1 induction course adverse cytogenetic abnormality diagnosis No acute promyelocytic leukemia No chronic myeloid leukemia blast transformation No prior relapse second great remission PATIENT CHARACTERISTICS : Age : Any age Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Creatinine clearance least 30 mL/min Other : No active malignancy Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2006</verification_date>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>adult acute erythroid leukemia ( M6 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>childhood acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>childhood acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>childhood acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>childhood acute monoblastic leukemia ( M5a )</keyword>
	<keyword>childhood acute monocytic leukemia ( M5b )</keyword>
	<keyword>childhood acute erythroleukemia ( M6 )</keyword>
	<keyword>childhood acute megakaryocytic leukemia ( M7 )</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>childhood acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>